Comparing statin strengths: why the milligram number is not the whole story
Statin strength is judged mainly by the expected percentage reduction in LDL cholesterol, not by comparing the milligram numbers printed on different products. A smaller number on one statin can represent a similar treatment intensity to a larger number on another. The prescribed ingredient, response on blood tests, other medicines and individual risk all matter.
Key takeaways
- Milligrams compare the amount of one ingredient; they do not provide a universal potency scale across different statins.
- Guidelines group statin regimens by expected LDL-lowering intensity, but an individual’s measured response and treatment goal still matter.
- Interactions, liver or kidney function, pregnancy, side effects and the reason for treatment can change which comparisons are clinically meaningful.
Why can a lower milligram number be a stronger statin?
A milligram is a unit of mass, not a score. Ten milligrams of atorvastatin and ten milligrams of rosuvastatin are amounts of two different molecules. Their absorption, transport into the liver, metabolism and effect on LDL receptors differ. Reading the larger number as “stronger” is therefore like comparing two liquids by spoonful without asking what each liquid contains.
Recognised guidelines deal with this by classifying particular statin-and-strength combinations as low, medium or high intensity according to their expected LDL reduction. For example, the current NICE lipid guideline places some atorvastatin and rosuvastatin strengths in the same high-intensity band while placing commonly used simvastatin strengths in a medium-intensity band. That is a population-level comparison, not a conversion instruction.
What does “high-intensity” actually mean?
“Intensity” describes the average LDL-cholesterol reduction expected from a regimen in study populations. It does not mean that every person will obtain that exact reduction, that a high-intensity option is automatically appropriate, or that all products in one band are interchangeable.
| Label or result | What it can tell you | What it cannot tell you |
|---|---|---|
| Milligrams on one statin | The amount of that ingredient | How it compares directly with a different statin |
| Guideline intensity band | Expected LDL-lowering range in populations | One person’s exact response or suitability |
| Follow-up lipid result | The observed change after treatment | Whether every future result will be identical |
| Brand name | Which marketed product is supplied | Ingredient, strength or formulation without checking the label |
The practical comparison is therefore not simply tablet against tablet. Clinicians consider the starting lipid profile, the intended reduction or target, and the result after treatment. NICE recommends assessing response and adherence rather than assuming that the printed strength predicts the entire outcome.
Are atorvastatin, rosuvastatin and simvastatin interchangeable?
No automatic substitution should be inferred. They belong to the same medicine class and all reduce LDL cholesterol, but they are distinct ingredients. Atorvastatin, rosuvastatin and simvastatin have different intensity ranges, metabolic pathways, interaction profiles and prescribing constraints.
This distinction matters when someone sees a numerically smaller strength after a prescription change and worries that treatment has been “reduced”. Forum discussions repeatedly show the opposite error too: people treat an online equivalence chart as permission to calculate a replacement themselves. Such charts summarise expected LDL effects; they do not account for why a particular statin was selected, nor do they make two tablets exchangeable.
Differences can also appear between a statin alone and a combination product. A tablet containing a statin plus another lipid-lowering ingredient cannot be compared with a statin-only tablet by looking at the statin milligrams alone.
Why might the same statin work differently for two people?
Expected intensity is an average. Baseline LDL level, adherence, underlying lipid disorder, diet, other health conditions and biological variation can influence the measured response. A result that changes less than expected may prompt a clinician to check how the medicine is being taken, interactions or secondary causes before interpreting it as a simple potency problem.
Side effects are not a reliable potency meter either. Muscle symptoms can have several causes, while statins can rarely cause serious muscle injury or liver problems. The absence of symptoms does not prove that a regimen is ineffective, and symptoms do not establish that another statin would be equivalent or preferable.
What changes the answer?
The clinically relevant comparison may change with:
- The treatment purpose. Primary prevention, established cardiovascular disease and inherited lipid disorders do not carry the same baseline risk or treatment objectives.
- Kidney or liver function. These can affect medicine choice, precautions and monitoring.
- Other medicines and foods. Some antibiotics, antifungals, antivirals, cardiovascular medicines and grapefruit products can interact with particular statins. FDA simvastatin labelling illustrates why restrictions can be ingredient-specific.
- Pregnancy, pregnancy planning or breastfeeding. These require a specific discussion rather than comparison from a chart.
- Previous adverse effects. The symptom, timing, laboratory findings and response to clinical assessment matter more than an online ranking.
Which warning signs need prompt assessment?
Seek prompt medical advice for unexplained muscle pain, tenderness or weakness, especially if it is severe or accompanied by fever, marked tiredness or dark urine. Yellowing of the skin or eyes, unusually pale stools, dark urine or significant upper-abdominal discomfort also need assessment. Call emergency services for symptoms of a heart attack or stroke; a statin does not make new chest pain, facial droop, arm weakness or speech difficulty safe to watch at home.
For a useful medicine review, bring the exact product labels, an up-to-date medicines and supplements list, and available lipid results. Ask what LDL reduction is being sought, how response will be assessed, and which interactions apply to the specific ingredient. Do not use a potency table to change or exchange statins yourself.
Sources
- NICE: Cardiovascular disease: risk assessment and reduction, including lipid modification.
- Singapore HealthHub: Atorvastatin.
- FDA: ZOCOR (simvastatin) prescribing information.
- Reddit r/Cholesterol: Atorvastatin and Rosuvastatin change? Used only as a reader-question signal, not medical evidence.
